Transcutaneous Spinal Cord Stimulation Enables Recovery of Walking in Children with Acute Flaccid Myelitis Go to source) ...

This systematic review and network meta-analysis found that spinal cord stimulation therapies for treatment of chronic pain in back and/or lower extremities were associated with greater improvements ...

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the ...

This systematic review and network meta-analysis found that spinal cord stimulation therapies for treatment of chronic pain ...

Researchers at Kennedy Krieger Institute report that Transcutaneous Spinal Cord Stimulation (TSS) combined with movement ...

US-based device company Nevro has secured market authorisation from the European Union (EU) for its HFX iQ spinal cord ...

A key highlight of the quarter came right at the end when Nevro won FDA approval for HFX AdaptiveAI, an AI-powered, ...

The global spinal cord stimulators market is on a robust growth trajectory, poised to reach an impressive valuation of USD 5,441.4 million by 2033. Currently valued at USD 2,702.7 million in 2023, the ...

Nevro's HFX iQ spinal cord stimulator earned the European Union's CE mark, the company said Nov. 12.